Project
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
Ongoing - recruitment active · 2023 until 2028
Baumann Michael, Harder Anja, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Ongoing - recruitment active
Start Date
2023
End Date
2028
Financing
Industry
Labels
myeloma